GlassScriptPhysician profile
Brian J Horner
NPI 1336465939
$20,729.55
in general payments reported to CMS, 2019-2025
40 companies · $7,272 in 2025
The $7,272 reported for 2025 was more than what 98% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $918 · 2020: $302 · 2021: $1,135 · 2022: $1,338 · 2023: $1,910 · 2024: $7,855 · 2025: $7,272.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,552 · Honoraria: $3,450 · Consulting Fee: $2,975 · Travel and Lodging: $1,519 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,300 · Education: $241.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,552.34 |
| Honoraria | $3,450.00 |
| Consulting Fee | $2,975.00 |
| Travel and Lodging | $1,518.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,300.00 |
| Education | $241.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $5,235.92 | 2024-2025 | Rezdiffra, Resmetirom |
| Mirum Pharmaceuticals, INC. | $3,045.26 | 2025 | Livmarli |
| Abbvie INC. | $2,608.66 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $2,206.69 | 2019-2025 | Entyvio, Eohilia |
| Pfizer INC. | $1,666.50 | 2019-2025 | |
| Janssen Biotech, INC. | $1,082.16 | 2019-2025 | Stelara, Tremfya, Simponi Aria |
| Boston Scientific Corporation | $969.89 | 2019-2025 | General - Biliary Devices, Axios, Resolution 360 Clip |
| Gilead Sciences, INC. | $368.24 | 2019-2025 | |
| Intercept Pharmaceuticals, INC. | $359.77 | 2019-2025 | Ocaliva |
| Genzyme Corporation | $325.26 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $287.97 | 2022-2025 | Dupixent |
| Medtronic, INC. | $274.63 | 2021-2025 | Pillcam, Bravo |
| Phathom Pharmaceuticals, INC. | $259.75 | 2024-2025 | Voquezna |
| Regeneron Pharmaceuticals, INC. | $257.75 | 2023-2025 | Dupixent |
| Celgene Corporation | $183.78 | 2022-2024 | Zeposia |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $153.92 | 2023-2025 | Omvoh |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $149.52 | 2019-2024 | Xifaxan, Trulance |
| Nestle Healthcare Nutrition INC. | $136.66 | 2021-2023 | |
| Braintree Laboratories, INC. | $134.37 | 2021-2024 | Suflave |
| Janssen Scientific Affairs, LLC | $119.14 | 2023-2025 | Tremfya, Stelara |
| Laborie Medical Technologies Corp. | $116.42 | 2023 | |
| Ucb, INC. | $110.75 | 2019 | |
| Conmed Corporation | $83.29 | 2021-2025 | Conmed Hemostasis, Conmed Dilation |
| Allergan, INC. | $71.76 | 2019 | |
| Merck Sharp & Dohme LLC | $66.49 | 2019-2024 | Zerbaxa, Dificid |
| Daiichi Sankyo INC. | $65.54 | 2020-2022 | |
| Redhill Biopharma INC. | $63.66 | 2021-2023 | Aemcolo, Talicia, Movantik |
| Mallinckrodt Hospital Products INC. | $59.68 | 2023-2024 | Terlivaz |
| Olympus America INC. | $45.77 | 2021-2022 | |
| Organon LLC | $33.32 | 2023 | Renflexis, Hadlima |
| Orphalan INC | $29.99 | 2025 | Cuvrior |
| Shire North American Group INC | $29.35 | 2019 | |
| Celltrion USA INC. | $28.36 | 2024 | Vegzelma |
| Novo Nordisk INC | $18.24 | 2025 | Wegovy |
| Aimmune Therapeutics, INC. | $16.73 | 2024 | |
| Ardelyx, INC. | $15.94 | 2025 | Ibsrela |
| Alfasigma USA, INC. | $15.60 | 2021 | |
| Ethicon US, LLC | $14.19 | 2019 | |
| Qol Medical, LLC | $12.94 | 2021 | |
| Echosens North America, INC. | $5.69 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Horner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.